Last reviewed · How we verify
GSK557296
At a glance
| Generic name | GSK557296 |
|---|---|
| Also known as | 50 mg, 150 mg |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban Administered in Repeat Doses in Healthy Women Volunteers (PHASE1)
- Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female Volunteers (PHASE1)
- A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation (PHASE2)
- Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers After Single and Repeat Dosing (PHASE1)
- A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban (PHASE1)
- Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis (PHASE2)
- A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK557296 CI brief — competitive landscape report
- GSK557296 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI